What Is the BALANCE Pilot Program?
The Trump administration launched an ambitious plan to bring affordable weight loss drugs to Medicare beneficiaries. The initiative, called BALANCE, aimed to test whether covering GLP-1 medications — like Wegovy and Zepbound — could save money or improve health outcomes among seniors. However, the program has hit a major wall. Insurers have declined to join, forcing the government to rethink how it delivers these drugs entirely.
Medicare currently prohibits coverage of weight loss medications. To move forward, the administration proposed waiving that restriction specifically for this pilot. The goal was clear: expand access while keeping costs low. Yet the plan depended heavily on insurer cooperation — and that cooperation never came.
Why the Pilot Needed Insurer Buy-In
The BALANCE program required private insurers to participate voluntarily. Without their involvement, the pilot could not function as originally designed. Moreover, insurers faced a likely financial burden by joining. The structure of the program placed cost responsibilities on them that many found unsustainable. As a result, they walked away from the table.
Why Insurers Refused to Participate
Insurers rejected the BALANCE program for financial reasons. The model required them to absorb costs that the program’s structure did not adequately offset. Consequently, participation would have strained their bottom lines.
The drugmakers — Eli Lilly and Novo Nordisk — agreed to sell the treatments at $245 per month for Medicare and Medicaid. Meanwhile, the government promised that seniors would pay only $50 per month. That gap between the drug price and the beneficiary copay created a funding challenge. Furthermore, insurers saw no clear mechanism to recover those costs over time.
The Financial Strain That Drove Insurers Away
Unlike traditional drug benefits where insurers can structure premiums and cost-sharing, this pilot offered limited flexibility. Therefore, insurers concluded that joining would expose them to losses without adequate compensation. Their refusal effectively unraveled the original plan.
How the Trump Administration Struck the Original Drug Deal
In late 2025, the Trump administration negotiated directly with Eli Lilly and Novo Nordisk. The deal lowered the prices of their popular obesity drugs significantly. In exchange, the administration committed to expanding access through Medicare and Medicaid. This was a notable policy move, given that Medicare law has long barred coverage of weight loss drugs.
The administration framed the arrangement as a win-win. Drugmakers would gain access to a massive new market. In return, seniors would benefit from lower prices. Additionally, taxpayers could potentially see savings if the drugs reduced obesity-related health complications down the road.
Why This Deal Was Unusual
Typically, Medicare drug price negotiations happen through formal channels. This deal, however, was brokered directly between the White House and pharmaceutical manufacturers. Thus, it bypassed some of the traditional structures of drug pricing policy. Critics and supporters alike noted this as a significant departure from standard practice.
The $50 Copay Promise for Seniors
One of the program’s most attractive features was the $50 monthly copay for seniors. For drugs that regularly cost over $1,000 per month without insurance, this represented dramatic savings. However, the promise raised an immediate question: who would cover the difference?
With the drugmakers selling at $245 per month and seniors paying $50, a gap of $195 remained. Under the original pilot design, insurers would have absorbed much of that cost. Now that insurers have walked away, the government must fund the program through a different channel — outside the standard Medicare Part D drug benefit structure.
CMS Steps In With an Alternative Funding Path
The Centers for Medicare and Medicaid Services (CMS) confirmed it will maintain the $50 copay for seniors through 2027. Rather than routing the benefit through Medicare Part D, CMS will cover the drugs through a separate funding mechanism. This keeps the promise to beneficiaries intact, even as the program’s original architecture has collapsed.
What Happens Next for Medicare Beneficiaries
Seniors enrolled in the program will not lose access immediately. CMS has committed to sustaining the $50 copay arrangement through 2027. However, the long-term future of GLP-1 coverage in Medicare remains uncertain.
The collapse of insurer participation raises questions about whether a sustainable model exists. Furthermore, it highlights the difficulty of expanding drug access when the financial incentives for key stakeholders do not align. Policymakers will now need to find a new framework if they want to make this coverage permanent.
Broader Implications for GLP-1 Drug Access
The BALANCE program’s struggles reflect a wider tension in U.S. health policy. GLP-1 drugs are among the most effective obesity treatments ever developed. Yet their high prices make broad coverage difficult, especially within existing Medicare structures.
The administration’s direct negotiations with Eli Lilly and Novo Nordisk showed one path forward. However, this episode demonstrates that drug company discounts alone are not enough. Insurer participation, funding structures, and regulatory frameworks must all align for such programs to work at scale.
